Rationale of using different biological therapies in rheumatoid arthritis. - Wikidata - wikimedia - TriplyDB

Rationale of using different biological therapies in rheumatoid arthritis.

Rationale of using different biological therapies in rheumatoid arthritis.

http://www.wikidata.org/entity/Q34153073

about

Inhibition of cytokine response to TLR stimulation and alleviation of collagen-induced arthritis in mice by Schistosoma japonicum peptide SJMHE1.Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab.Challenges for the pharmaceutical technical development of protein coformulations.

P2860

Q37662876-0FCDA17B-255D-47AF-B3BB-A59CCCFEAC9B Q38075801-41EABC6E-3B8D-4B63-996B-49331D3B9A29 Q38085279-0BF96948-43EF-4609-9EB2-9215B57A1AC0 Q39282825-25C4AA7E-E9BD-4E5D-A3C2-54F79E01308B

P2860

Rationale of using different biological therapies in rheumatoid arthritis.

http://www.wikidata.org/entity/Q34153073

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Rationale of using different biological therapies in rheumatoid arthritis.

@ast

Rationale of using different biological therapies in rheumatoid arthritis.

@en

Rationale of using different biological therapies in rheumatoid arthritis.

@nl

type

label

Rationale of using different biological therapies in rheumatoid arthritis.

@ast

Rationale of using different biological therapies in rheumatoid arthritis.

@en

Rationale of using different biological therapies in rheumatoid arthritis.

@nl

prefLabel

Rationale of using different biological therapies in rheumatoid arthritis.

@ast

Rationale of using different biological therapies in rheumatoid arthritis.

@en

Rationale of using different biological therapies in rheumatoid arthritis.

@nl

P1433

Q34153073-A0C0FD80-44FA-44D7-B7DE-52DEBD2D4A80

P1476

Q34153073-849A7B19-AB24-4F10-AA10-550726582262

P2093

Q34153073-37992028-1A0B-430C-BF70-0758959A72CB

P2860

Q34153073-0A38D347-FD63-4E9C-BD49-6C2E169B4DAD

Q34153073-1179F330-B813-4F68-AF98-E987B48B73B2

Q34153073-128A01AA-E33D-4BA8-A1B6-B42FCC759318

Q34153073-12FEDEA4-CB58-494A-9AAB-58C03E11A739

Q34153073-14709EDC-6D82-41CD-BDAD-FD8BB82BFCAC

Q34153073-1B8CFD11-FDAB-4B67-8884-9F31A3FA53B7

Q34153073-1CB5DA2F-A643-49BE-B428-4721BB893927

Q34153073-3597BC9A-89EA-4E73-B3C5-C50F9278B799

Q34153073-43C94472-4ACB-4C6C-865E-CAA5633708E4

Q34153073-46EB0760-5A24-40EF-90F1-6EAE0B940EA4

P2888

Q34153073-280009C0-2784-4677-8C81-485B5242EFBB

P304

Q34153073-BB732AA3-4D37-451D-911B-CC087FC7529F

P31

Q34153073-72DAE964-7F7D-4021-B0A5-9749ADF84E99

Q34153073-EF8F3871-E17B-4E07-901D-0E7878D5ABCA

P356

Q34153073-041CBEF4-F1EB-4CAB-A605-E8142A6170B1

P433

Q34153073-56A7A3E0-BFB2-4C3A-A7D1-DFB1D73F6091

P478

Q34153073-2CB9B4ED-7F06-4F77-869E-AA9A5C68DEB9

P50

Q34153073-4B964FFF-1732-474A-9839-5D0552437381

P577

Q34153073-7F8C4996-0A41-4C2D-A05C-5BE34C370DF9

P5875

Q34153073-C9D11AF4-95DB-4994-BB81-B645B0F5F527

P6179

Q34153073-CE70BBED-75B2-4753-82A1-BF44F1D0DB58

P698

Q34153073-5A6B5088-8B07-4886-9965-2BBAD75889D5

P921

Q34153073-3A33551A-1F48-4BD9-AE1C-573C0367961B

Q34153073-6265B709-B2A3-4259-AE3D-06B051C9D73F

Q34153073-83707416-F275-4C39-88CE-35C250CC9703

Q34153073-A80F568A-1CB9-409D-83DB-35DC15FD34C7

P932

Q34153073-715AA46C-C683-4BD7-AE4A-F02243E56A95

P356

P1433

Arthritis Research and Therapy

P1476

Rationale of using different biological therapies in rheumatoid arthritis.

@en

P2093

Matthias Geyer

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic dr

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Treating rheumatoid arthritis to target: recommendations of an international task force.

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

P2888

P304

214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR3102

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Ulf Müller-Ladner

P577

2010-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45827224

http://www.w3.org/2001/XMLSchema#string

P6179

1039102425

http://www.w3.org/2001/XMLSchema#string

P698

20735862

http://www.w3.org/2001/XMLSchema#string

P921

rheumatoid arthritis

monoclonal antibody

P932

2945050

http://www.w3.org/2001/XMLSchema#string